EP. 1: Addressing the Most Critical Treatment Questions in EGFR-mutant Advanced NSCLC
July 8th 2025
On May 31, 2025, a select group of US medical and thoracic oncologists from academic and cancer specialty institutions participated in a workshop held in conjunction with the 2025 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The participants discussed current and emerging therapeutic strategies in treating patients with EGFR-mutant (EGFRm), advanced non–small cell lung cancer (NSCLC). The session was moderated by Helena Yu, MD, who led discussions on managing the balance between improved efficacy outcomes and increased toxicity with combination therapies, and sequencing strategies for first-line and subsequent treatments.
